TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3318377
Drug: High-dose carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carbonyl iron 600 mg three times per day
Study: 3318377
Drug: Standard ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ferrous sulfate 60 mg three times per day
Study: 29967325
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BC6 and Deceleration Capacity (DC)
Study: 29967325
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PE and Deceleration Capacity (DC)
Study: 27079740
Drug: Mizoribine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine and steroid
Study: 27079740
Drug: Cyclophosphamide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide and steroid
Study: 25840742
Drug: Metoclopramide (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (dopamine D2-receptor antagonist)
Study: 17014912
Drug: Occupational therapy‐led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy‐led lifestyle treatment
Study: 15482080
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment plus abstinent-contingent housing and work (DT+)
Study: 15482080
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment only (DT)
Study: 9625308
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg three times daily)
Study: 7574219
Drug: Aspirin, 325
Normalized name: Aspirin, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 325 mg/d
Study: 2168814
Drug: Qigong and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong and antihypertensive drugs at low dosage
Study: 2168814
Drug: WM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM group (antihypertensive drugs alone)
Study: 30156030
Drug: Low CoQ10
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low CoQ10 levels (<0.5 μg/mL) in patients with acute influenza
Study: 28359749
Drug: Multidomain intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidomain intervention plus omega 3 polyunsaturated fatty acids (800 mg DHA and 225 mg EPA daily)
Study: 23565930
Drug: Prilocaine irrigation
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilocaine irrigation (30 mL of 2% prilocaine)
Study: 23565930
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prilocaine-free irrigation solution)
Study: 10911005
Drug: Continued medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medical treatment
Study: 7931883
Drug: Combination phototherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination phototherapy
Study: 30130712
Drug: Sarcosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (2 g)
Study: 18984493
Drug: Group-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based program for obese children and adolescents consisting of modules for physical activity, nutritional education, and coping strategies performed twice each week for 1 year with parental participation and medical supervision.
Study: 12582838
Drug: GABA(A) agonist
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA(A) agonist lorazepam
Study: 9206051
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen therapy (20mg daily for 2 to 5 years)
Study: 9206051
Drug: No tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tamoxifen therapy (control group)
Study: 2835055
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 2,500 U s.c. once daily
Study: 2835055
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5,000 U s.c. twice daily with dihydroergotamine (DHE) 0.5 mg s.c.
Study: 30064032
Drug: Palm oil
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palm oil plus Sn solution
Study: 30064032
Drug: Sn solution
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sn solution (positive control)
Study: 28283026
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate injection (DMPA)
Study: 28283026
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill (COCP)
Study: 23735957
Drug: Intraventricular application
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular application of recombinant tissue‐type plasminogen activator and lateral rotational therapy (experimental)
Study: 20464617
Drug: GONB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + triamcinolone 40 mg (group B)
Study: 14609894
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1 g of EMLA 60 to 90 minutes before lumbar puncture
Study: 8677067
Drug: Dexamethasone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (5 mg every 12 hours for a total of four doses)
Study: 1464896
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg single dose)
Study: 1464896
Drug: Captopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (2 x 25 mg for two weeks)
Study: 24270933
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine 0.1 mg/kg with promethazine 25 mg
Study: 24270933
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine 0.1 mg/kg
Study: 22506833
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection with the X‐Tip system
Study: 22506833
Drug: Periodontal ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal ligament injections (PDL)
Study: 16285944
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human PYY3-36 (highest dose)
Study: 2143063
Drug: Intravenous fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fluorouracil
Study: 422100
Drug: Benzbromarone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone (50 mg to 100 mg/day)
Study: 21874538
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg once daily for 12 weeks
Study: 21874538
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg once daily for 12 weeks
Study: 2888253
Drug: Morphine-Scopolamine (Mo-Scop)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-Scopolamine (Mo-Scop)
Study: 27667332
Drug: Intradermal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal delivery of virosomal vaccine using MicronJet600™
Study: 27667332
Drug: 45μg dose
Normalized name: tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45μg dose of virosomal vaccine formulation
Study: 25266414
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rate of 2 l/min (group D2)
Study: 25266414
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rate of 4 l/min (group D4)
Study: 25266414
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rate of 6 l/min (group D6)
Study: 22644708
Drug: Insulin-loaded HA
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-loaded HA nanoparticles
Study: 22644708
Drug: Insulin solution
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin solution
Study: 20356587
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral contraceptives (OC) and prednisolone (OC/Pr)
Study: 18177922
Drug: High-dose lumiracoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lumiracoxib
Study: 10925684
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (CMF: cyclophosphamide 100 mg/body on days 1‐14; methotrexate 40 mg/m2 on days 1 and 8; 5‐fluorouracil 500 mg/m2 on days 1 and 8)
Study: 10925684
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (UFT 300 mg/day and tamoxifen 30 mg/day for 2 years)
Study: 8844884
Drug: Radiotherapy doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy doses ranging from 0.4 to 5.2 Gy per fraction
Study: 8844884
Drug: Radiotherapy doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy doses less than 1.5 Gy per fraction
Study: 8844884
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment fractions (5, 10, 12, and 20 daily treatment fractions)
Study: 4029019
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (0.5g and 1g)
Study: 16210963
Drug: Alemtuzumab with
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab with low-dose cyclosporine (CsA)
Study: 16210963
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (full doses of CsA with azathioprine and corticosteroids)
Study: 12078913
Drug: Escalated BEACOPP
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated BEACOPP (four escalated cycles followed by four at baseline dose)
Study: 7545380
Drug: DDAVP infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP infusion (group I)
Study: 7545380
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (group II)
Study: 30353743
Drug: Lixisenatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (20 μg, 8 weeks)
Study: 30353743
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (titrated once-daily)
Study: 23795871
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance use treatment (Brief Strategic Family Therapy)
Study: 18819961
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (>/=200 mg)
Study: 18819961
Drug: Moderate-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose aspirin (101-199 mg)
Study: 18819961
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (</=100 mg)
Study: 18819961
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (>/=200 mg) vs Low-dose aspirin (</=100 mg)
Study: 7977774
Drug: 10% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% amino acid solution infused at 0.5 ml.kg‐1.min‐1 (group I)
Study: 7977774
Drug: 10% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% amino acid solution infused at 1.0 ml.kg‐1.min‐1 (group II)
Study: 7977774
Drug: 10% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% amino acid solution infused at 2.0 ml.kg‐1.min‐1 (group III)
Study: 7977774
Drug: 10% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% amino acid solution infused at 4.0 ml.kg‐1.min‐1 (group IV)
Study: 7977774
Drug: 10% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% amino acid solution infused at 6.0 ml.kg‐1.min‐1 (group V)
Study: 31868684
Drug: Levodopa (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (regular dose)
Study: 26750388
Drug: 12-week Cognitive
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week Cognitive Behavioural Therapy-based group treatment for hoarding disorder
Study: 21789385
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 1.5 ng/mL (group I)
Study: 21789385
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 2 ng/mL (group II)
Study: 21789385
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 2.5 ng/mL (group III)
Study: 16954359
Drug: Low-polyphenol olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-polyphenol olive oil (2.7 mg/kg)
Study: 16954359
Drug: Medium-polyphenol olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-polyphenol olive oil (164 mg/kg)
Study: 16954359
Drug: High-polyphenol olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-polyphenol olive oil (366 mg/kg)
Study: 11361046
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) oxycodone q12h
Study: 11361046
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) oxycodone qid
Study: 29931358
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg (2400 IU)/d of D3
Study: 29931358
Drug: 20 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg/d of 25(OH)D3
Study: 23154532
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline based on insulin intensive therapy
Study: 10223232
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with alpha-fetoprotein level <10 ng/mL
Study: 28698075
Drug: Metformin (1500mg/day)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (1500mg/day) with Clomiphene citrate (100mg/day)
Study: 20727236
Drug: Juice Plus+®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice Plus+® (dietary supplement from fruits and vegetables)
Study: 19165198
Drug: Standard AC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard AC (doxorubicin 60 mg m(‐2) + cyclophosphamide 600 mg m(‐2) every 3 weeks)
Study: 19165198
Drug: Accelerated AC
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated AC (doxorubicin 60 mg m(‐2) + cyclophosphamide 600 mg m(‐2) every 2 weeks with pegfilgrastim)
Study: 19165198
Drug: Combined EC
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined EC (epirubicin 90 mg m(‐2) every 3 weeks or every 2 weeks with pegfilgrastim)
Study: 14505238
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of parenteral Cefazolin preoperatively
Study: 9022487
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin and heparin (5000 U of unfractionated heparin subcutaneously 12 hourly)
Study: 29926217
Drug: Test lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Test lenalidomide capsule (25 mg)
Study: 29926217
Drug: Revlimid® capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revlimid® capsule (25 mg)
Study: 19842347
Drug: Notched noise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Notched noise stimuli (windowed sound therapy [WST])
Study: 15468963
Drug: CsA alone
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA alone (2-3 mg/kg/d)
Study: 15468963
Drug: CsA after
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA after intravenous pulse methylprednisolone therapy (CsA/PMT) (2-3 mg/kg/d)
Study: 15468963
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (PSL, 40-60 mg/d)
Study: 9309990
Drug: Mannitol inhalation
Normalized name: mannitol inhalation kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol inhalation (5, 10, 20, or 40 mg to a cumulative dose of 635 mg)
Study: 9309990
Drug: Mannitol inhalation
Normalized name: mannitol inhalation kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol inhalation (first challenge)
Study: 9309990
Drug: Mannitol inhalation
Normalized name: mannitol inhalation kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol inhalation (second challenge)
Study: 30786829
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (10 mg/day)
Study: 27282852
Drug: Gambrosol Trio
Normalized name: Simparica TRIO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gambrosol Trio (biocompatible PD solution)
Study: 27282852
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD solution (Dianeal)
Study: 27282852
Drug: Gambrosol Trio
Normalized name: Simparica TRIO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gambrosol Trio and Standard PD solution
Study: 20417925
Drug: Subconjunctival ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered 3 days prior to surgery (Group 1, n = 5)
Study: 20417925
Drug: Subconjunctival ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered at the time of surgery (Group 2, n = 5)
Study: 16003294
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d of simvastatin
Study: 16003294
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d of atorvastatin
Study: 7549167
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine with 2 micrograms/ml fentanyl via PCEA
Study: 7549167
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine with 2 micrograms/ml fentanyl via continuous epidural infusion (CEI)
Study: 1940776
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (3 g daily)
Study: 1940776
Drug: Acipimox (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (0.75 g daily)
Study: 6779890
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (4 mg)
Study: 6779890
Drug: Tablet (4
Normalized name: KISQALI Tablet (400mg daily dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (4 mg)
Study: 31395485
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (TA) at a dose of 2 mg kg‐1 IV and then IM
Study: 31395485
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (TA) at a dose of 4 mg kg‐1 IV
Study: 28618772
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of pitavastatin
Study: 28618772
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of pitavastatin
Study: 22975753
Drug: tissue inhibitor
Normalized name: Tissue inhibitor of metalloproteinases 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tissue inhibitor of metalloproteinases-1 (TIMP-1)
Study: 17462615
Drug: roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (150 mg) and ambroxol HCl (30 mg) dispersible tablet (treatment A)
Study: 17462615
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg roxithromycin dispersible tablet and 30 mg ambroxol HCl tablet (treatment B)
Study: 17462615
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg roxithromycin dispersible tablet (treatment C)
Study: 17462615
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ambroxol HCl tablet (treatment D)
Study: 11296098
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (150 microg)
Study: 11296098
Drug: CCK‐4 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐4 administration
Study: 9247907
Drug: Metformin (Glucophage)
Normalized name: metformin Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (Glucophage) with standard diet and exercise
Study: 9247907
Drug: Troglitazone (investigational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (investigational drug) with standard diet and exercise
Study: 8290882
Drug: Miconazole chewing
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole chewing gum (3.6 mg, four times daily)
Study: 8290882
Drug: Miconazole gel
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole gel (50 mg, four times daily)
Study: 3326678
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin 600 mg
Study: 25516196
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg 3× daily via nasogastric tube for 21 days